Table 1.
Baseline Characteristics of Study Participants Assigned to an Efavirenz-Containing Regimen
| Characteristic | CYP2B6/CYP2A6 Genotype Data Available, No. (%)a | Overall, No. (%)a (n = 2239) | |
| Yes (n = 1833) | No (n = 406) | ||
| Parent study | |||
| A5095 | 635 (35) | 105 (26) | 740 (33) |
| A5142 | 403 (22) | 70 (17) | 473 (21) |
| A5175 | 104 (6) | 32 (8) | 136 (6) |
| A5202 | 691 (38) | 199 (49) | 890 (40) |
| Sex | |||
| Male | 1510 (82) | 316 (78) | 1826 (82) |
| Female | 323 (18) | 90 (22) | 413 (18) |
| Race/ethnicity | |||
| White non-Hispanic | 781 (43) | 121 (30) | 902 (40) |
| Black non-Hispanic | 660 (36) | 166 (41) | 826 (37) |
| Hispanic | 392 (21) | 119 (29) | 511 (23) |
| Age, y | |||
| Median (IQR) | 38 (31–44) | 38 (30–44) | 38 (31–44) |
| Range | 17–77 | 19–71 | 17–77 |
| CD4 T-cell count, cells/μLb | |||
| Median (IQR) | 218 (75–330) | 188 (64–295) | 212 (73–322) |
| Range | 0–1336 | 1–849 | 0–1336 |
| HIV-1 RNA, log10 copies/mL | |||
| Median (IQR) | 4.74 (4.39–5.24) | 4.74 (4.40–5.22) | 4.74 (4.39–5.24) |
| Range | 2.34–7.04 | 2.76–6.71 | 2.34–7.04 |
| History of AIDS | 326 (18) | 63 (16) | 389 (17) |
| History of injection drug use | 174 (9) | 49 (12) | 223 (10) |
| Psychiatric history or psychoactive medication | 711 (39) | 148 (36) | 859 (38) |
| Psychoactive medication | 310 (17) | 69 (17) | 379 (17) |
| Depression-related history or antidepressant medication | 459 (25) | 94 (23) | 553 (25) |
| Antidepressant medication | 239 (13) | 53 (13) | 292 (13) |
| Body mass index (kg/m2)c | |||
| Median (IQR) | 24.6 (22.0–27.8) | 24.9 (22.2–27.9) | 24.7 (22.1–27.8) |
| Range | 13.9–60.6 | 17.1–53.8 | 13.9–60.6 |
Abbreviations: HIV-1, human immunodeficiency virus type 1; IQR, interquartile range.
aData represent No. (%) of participants unless otherwise specified.
bThis analysis included 2237 participants (1831 with and 406 without CYP2B6/CYP2A6 genotype data available).
cThis analysis included 2205 participants (1810 with and 395 without CYP2B6/CYP2A6 genotype data available).